McKesson Corporation: Beat — EPS $11.68, Revenue $110.96B
Earnings BeatQ2 2027 · After-market
Did McKesson Corporation (MCK) beat earnings today?
Yes, McKesson Corporation (MCK) beat Wall Street analyst expectations for Q2 2027, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+8.65% surprise
$11.68Actual
Expected: $10.75
vs. year ago +18.0%
Total Revenue+0.92% surprise
$110.96BActual
Expected: $109.95B
vs. year ago +8.0%
Released Nov 04 · 4:08 PM ET
Earning Report
| Metric | Q2 FY27 | Q2 FY26 | YoY Change % |
|---|---|---|---|
| Revenues | $110.96B | $103.15B | +8.0 |
| Revenue detail — reported lines | |||
| └─North American Pharmaceutical | $91.36B | $86.48B | +6.0 |
| └─Oncology & Multispecialty | $14.98B | $12.04B | +24.0 |
| └─Prescription Technology Solutions | $1.52B | $1.38B | +10.0 |
| └─Medical-Surgical Solutions | $3.10B | $2.95B | +5.0 |
| Net Income | $1.30B | $1.16B | +11.0 |
| GAAP Diluted EPS | $10.44 | $8.92 | +17.0 |
| GAAP Basic EPS | $10.47 | $8.95 | +17.0 |
| Adjusted EPS | $11.68 | $9.86 | +18.0 |
Financial Outlook / Guidance
| Metric | FY27 Outlook | |
|---|---|---|
| Guidance | Expected | |
| Adjusted Earnings per Diluted Share | $45.60-$46.40 (+17-19% YoY, prev. $44.20-$45.00 | $44.66Beat +3.00% |
FY27 Outlook
- Adjusted Earnings per Diluted Share
- Guidance$45.60-$46.40(+17-19% YoY, prev. $44.20-$45.00Expected$44.66Beat +3.00%
Business Highlights
- ➤Extended CVS Health pharmaceutical distribution partnership through June 2032.
- ➤Signed agreement to invest approximately $1.4B for approximately 49% of Option Care Health.
- ➤Completed acquisition of Precision Medicine Group on November 2, 2026.
- ➤PRISM Vision Group added Spectrum Vision Partners to its network.
- ➤PRISM Vision Group’s provider network now exceeds 350 providers.
- ➤Returned $3.6B to shareholders through repurchases and dividends during the first six months.
- ➤Repurchased $3.4B of common stock during the first six months.
- ➤Planned separation of the Medical-Surgical Solutions segment remains a stated strategic initiative.
Management Commentary
Brian Tyler, chair and chief executive officer
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise. We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline. We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders. As we close out a strong first half of our fiscal year, I want to thank Team McKesson for their unwavering commitment to excellence and for the impact they make across healthcare every day.”
Kenny Cheung, executive vice president and chief financial officer
“The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is underpinned by the strength in our business and the confidence we have in our ability to execute consistently. We are committed to building towards the future through disciplined capital deployment and strategic investments.”